
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6582041/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. Hepatology, 2022, 75, 13-27.	3.6	16
2	Clinical update on risks and efficacy of anti-SARS-CoV-2 vaccines in patients with autoimmune hepatitis and summary of reports on post-vaccination liver injury. Digestive and Liver Disease, 2022, 54, 722-726.	0.4	8
3	Coronavirus disease associated immune thrombocytopenia: Causation or correlation?. Journal of Microbiology, Immunology and Infection, 2021, 54, 531-533.	1.5	20
4	Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 936-942.	1.4	37
5	Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis. Nature Reviews Rheumatology, 2021, 17, 244-244.	3.5	11
6	Decompensated Cirrhosis as Presentation of LKM1/LC1 Positive Type 2 Autoimmune Hepatitis in Adulthood. A Rare Clinical Entity of Difficult Management. Gastroenterology Insights, 2021, 12, 67-75.	0.7	6
7	Autoantibodies to speckled protein family in primary biliary cholangitis. Allergy, Asthma and Clinical Immunology, 2021, 17, 35.	0.9	8
8	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Reports, 2021, 3, 100248.	2.6	33
9	Anti-neutrophil cytoplasm antibodies (ANCA) in autoimmune diseases: A matter of laboratory technique and clinical setting. Autoimmunity Reviews, 2021, 20, 102787.	2.5	8
10	Antinuclear antibodies in COVID 19. Clinical and Translational Science, 2021, 14, 1627-1628.	1.5	18
11	A practical histological approach to the diagnosis of autoimmune hepatitis: experience of an Italian tertiary referral center. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 937-945.	1.4	4
12	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. Gastroenterology, 2021, 160, 2483-2495.e26.	0.6	27
13	Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World Journal of Gastroenterology, 2021, 27, 2994-3009.	1.4	103
14	Acute-on-chronic liver failure: A complex clinical entity in patients with autoimmune hepatitis. Journal of Hepatology, 2021, 75, 1503-1505.	1.8	9
15	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. Journal of Hepatology, 2021, 75, 572-581.	1.8	62
16	Limitation of the simplified scoring system for the diagnosis of autoimmune Hepatitis with acute onset. Liver International, 2021, 41, 529-534.	1.9	14
17	Surrogate Markers for Antimitochondrial Antibody–Negative Primary Biliary Cholangitis. American Journal of Gastroenterology, 2021, 116, 215-217.	0.2	3
18	Standardization of Autoantibody Testing in Autoimmune Hepatitis. Clinical Reviews in Allergy and Immunology, 2020, 58, 39-39.	2.9	1

#	Article	IF	CITATIONS
19	Permanent immunosuppression in SLA/LPâ€positive autoimmune hepatitis is required although overall response and survival are similar. Liver International, 2020, 40, 368-376.	1.9	21
20	Editorial: gut microbiota profile in patients with autoimmune hepatitis—a clue for adjunctive probiotic therapy?. Alimentary Pharmacology and Therapeutics, 2020, 52, 392-394.	1.9	9
21	Diagnosis of primary biliary cholangitis in a "teen―male patient. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, e20-e21.	0.7	0
22	Acute liver injury and anorexia nervosa: a case report. Italian Journal of Medicine, 2019, 13, 128-131.	0.2	0
23	Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents. Journal of Autoimmunity, 2019, 102, 89-95.	3.0	16
24	Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms. Liver International, 2019, 39, 2124-2135.	1.9	10
25	Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System. Multiple Sclerosis Journal, 2019, 25, 1633-1640.	1.4	21
26	Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study. Digestive and Liver Disease, 2018, 50, 698-702.	0.4	21
27	Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis. Digestive Diseases and Sciences, 2018, 63, 1348-1354.	1.1	27
28	Autoimmune liver disease serology in acute hepatitis E virus infection. Journal of Autoimmunity, 2018, 94, 1-6.	3.0	39
29	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. The Lancet Gastroenterology and Hepatology, 2018, 3, 626-634.	3.7	103
30	Diagnostic approach to autoimmune hepatitis. Expert Review of Clinical Immunology, 2017, 13, 769-779.	1.3	11
31	Primary Biliary Cholangitis: advances in management and treatment of the disease. Digestive and Liver Disease, 2017, 49, 841-846.	0.4	23
32	Autoantibodies in antimithocondrial antibodies negative primary biliary cholangitis. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, e47.	0.7	2
33	Clinical implications of antimitochondrial antibody seropositivity in autoimmune hepatitis: a multicentre study. European Journal of Gastroenterology and Hepatology, 2017, 29, 777-780.	0.8	17
34	Antimitochondrial antibodies positive autoimmune hepatitis with acute onset. Scandinavian Journal of Gastroenterology, 2017, 52, 920-921.	0.6	1
35	Hyperferritinemia and hypergammaglobulinemia predict the treatment response to standard therapy in autoimmune hepatitis. PLoS ONE, 2017, 12, e0179074.	1.1	33
36	Predictive factors of poor response to therapy in Autoimmune Hepatitis. Digestive and Liver Disease, 2016, 48, 1078-1081.	0.4	23

#	Article	IF	CITATIONS
37	Features and Progression of Asymptomatic Autoimmune Hepatitis in Italy. Clinical Gastroenterology and Hepatology, 2016, 14, 139-146.	2.4	26
38	<i>De novo</i> autoimmune hepatitis in liver transplant: State-of-the-art review. World Journal of Gastroenterology, 2016, 22, 2906.	1.4	18
39	Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver International, 2015, 35, 636-641.	1.9	57
40	Autoimmune liver disease and concomitant extrahepatic autoimmune disease. European Journal of Gastroenterology and Hepatology, 2015, 27, 1175-1179.	0.8	60
41	Two of Them Do It Better: Novel Serum Biomarkers Improve Autoimmune Hepatitis Diagnosis. PLoS ONE, 2015, 10, e0137927.	1.1	9
42	Autoantibodies in Autoimmune Hepatitis. Digestive Diseases, 2015, 33, 65-69.	0.8	12
43	Type 1 and type 2 autoimmune hepatitis in adults share the same clinical phenotype. Alimentary Pharmacology and Therapeutics, 2015, 41, 1281-1287.	1.9	43
44	Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis. European Journal of Gastroenterology and Hepatology, 2014, 26, 532-537.	0.8	25
45	Smooth Muscle Autoantibodies. , 2014, , 491-495.		0
46	Factors Associated With Response to Therapy and Outcome ofÂPatients With Primary Biliary Cirrhosis With Features ofÂAutoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2014, 12, 863-869.	2.4	64
47	Antiâ€ribosomal P protein antibody: an autoreactivity devoid of prognostic value in patients with autoimmune hepatitis. Liver International, 2014, 34, 1446-1446.	1.9	4
48	The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies. Journal of Autoimmunity, 2013, 46, 74-80.	3.0	39
49	Review article: autoimmune hepatitis - current management and challenges. Alimentary Pharmacology and Therapeutics, 2013, 38, 887-913.	1.9	146
50	Antibodies to soluble liver antigen in patients with various liver diseases: A multicentre study. Liver International, 2013, 33, 190-196.	1.9	36
51	Diagnostic difficulties, therapeutic strategies, and performance of scoring systems in patients with autoimmune hepatitis and concurrent hepatitis B/C. Scandinavian Journal of Gastroenterology, 2013, 48, 504-508.	0.6	14
52	Identification of New Autoantigens by Protein Array Indicates a Role for IL4 Neutralization in Autoimmune Hepatitis. Molecular and Cellular Proteomics, 2012, 11, 1885-1897.	2.5	38
53	Sex Differences Associated with Primary Biliary Cirrhosis. Clinical and Developmental Immunology, 2012, 2012, 1-11.	3.3	37
54	Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases. European Journal of Gastroenterology and Hepatology, 2012, 24, 531-534.	0.8	100

#	Article	IF	CITATIONS
55	Regulatory T cell defects in adult autoimmune hepatitis. Journal of Hepatology, 2012, 57, 1154-1155.	1.8	4
56	Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. Expert Review of Molecular Diagnostics, 2012, 12, 65-74.	1.5	74
57	Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis. Annals of Hepatology, 2012, 11, 7-14.	0.6	36
58	Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis. Annals of Hepatology, 2012, 11, 7-14.	0.6	20
59	Redistribution of regulatory T-cells across the evolving stages of chronic hepatitis C. Digestive and Liver Disease, 2011, 43, 807-813.	0.4	8
60	A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology, 2010, 52, 999-1007.	3.6	175
61	Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis. Hepatology, 2010, 52, 1857-1857.	3.6	59
62	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nature Genetics, 2010, 42, 658-660.	9.4	389
63	PML Nuclear Body Component Sp140 Is a Novel Autoantigen in Primary Biliary Cirrhosis. American Journal of Gastroenterology, 2010, 105, 125-131.	0.2	69
64	Current topics in autoimmune hepatitis. Digestive and Liver Disease, 2010, 42, 757-764.	0.4	19
65	489 CLINICAL IMPACT AND BEHAVIOUR OF SERUM AUTOANTIBODIES IN ADULT LIVER TRANSPLANTATION. Journal of Hepatology, 2010, 52, S197-S198.	1.8	1
66	687 AN INCREASED T-CELL REGULATORY ACTIVITY IN CHRONIC HEPATITIS C CORRELATES WITH NORMAL TRANSAMINASES, BUT ALSO WITH ADVANCED LIVER DISEASE. Journal of Hepatology, 2010, 52, S267-S268.	1.8	0
67	698 IMPAIRED REGULATORY ABILITY AND PREDOMINANCE OF THE GAMMA-DELTA VDELTA1 SUBSET IN PATIENTS WITH HCV-RELATED TYPE 2 CRYOGLOBULINEMIA. Journal of Hepatology, 2010, 52, S271-S272.	1.8	1
68	Diagnosis and Therapy of Autoimmune Hepatitis. Mini-Reviews in Medicinal Chemistry, 2009, 9, 847-860.	1.1	35
69	Multiple nuclear dots and rim-like/membranous IgG isotypes in primary biliary cirrhosis. Autoimmunity, 2009, 42, 224-227.	1.2	14
70	Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients. Hepatology, 2009, 49, 1782-1783.	3.6	58
71	Autoimmune hepatitis in Italy: The Bologna experience. Journal of Hepatology, 2009, 50, 1210-1218.	1.8	133
72	Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C. Journal of Hepatology, 2009, 50, 1093-1101.	1.8	31

#	Article	IF	CITATIONS
73	The Serological Profile of the Autoimmune Hepatitis/Primary Biliary Cirrhosis Overlap Syndrome. American Journal of Gastroenterology, 2009, 104, 1420-1425.	0.2	111
74	665 PML NUCLEAR BODY COMPONENT SP140 IS A NOVEL AUTOANTIGEN IN PRIMARY BILIARY CIRRHOSIS. Journal of Hepatology, 2009, 50, S244.	1.8	0
75	877 INCREASED REGULATORY POTENTIAL AND IMBALANCE OF THE VDELTA1/VDELTA2 RATIO IN PATIENTS WITH DIFFERENT MANIFESTATIONS OF HEPATITIS C. Journal of Hepatology, 2009, 50, S319.	1.8	1
76	Human leukocyte antigen polymorphisms in italian primary biliary cirrhosis: A multicenter study of 664 patients and 1992 healthy controls. Hepatology, 2008, 48, 1906-1912.	3.6	120
77	Autoimmune liver disease 2007. Molecular Aspects of Medicine, 2008, 29, 96-102.	2.7	18
78	861 A COMPLEX IMMUNOREGULATORY DEFICIENCY CHARACTERISES TYPE 1 AUTOIMMUNE HEPATITIS. Journal of Hepatology, 2008, 48, S323.	1.8	1
79	Antimitochondrial Antibodies and Other Antibodies in Primary Biliary Cirrhosis: Diagnostic and Prognostic Value. Clinics in Liver Disease, 2008, 12, 261-276.	1.0	72
80	Clinical and serological profile of primary biliary cirrhosis in young and elderly patients. QJM - Monthly Journal of the Association of Physicians, 2008, 101, 505-506.	0.2	9
81	LKM1-Positive Type 2 Autoimmune Hepatitis Following Allogenic Hematopoietic Stem-Cell Transplantation. American Journal of Gastroenterology, 2008, 103, 1313-1314.	0.2	15
82	HCV and Autoimmunity. Current Pharmaceutical Design, 2008, 14, 1678-1685.	0.9	64
83	Antifilamentous Actin Antibodies by ELISA for the Diagnosis of Type 1 Autoimmune Hepatitis. American Journal of Gastroenterology, 2007, 102, 1131-1132.	0.2	4
84	Clinical and serological profile of primary biliary cirrhosis in men. QJM - Monthly Journal of the Association of Physicians, 2007, 100, 534-535.	0.2	14
85	[537] ANTI-LIVER KIDNEY MICROSOME TYPE ONE (ANTI-LKM1) POSITIVE HCV-RELATED CHRONIC LIVER DISEASE: PRESENTATION AND NATURAL HISTORY. Journal of Hepatology, 2007, 46, S204.	1.8	Ο
86	[664] DETECTION OF MND AND RL/M ANTI-NUCLEAR ANTIBODIES PATTERNS: A RELIABLE DIAGNOSTIC TOOL IN ANTI-MITOCHONDRIAL ANTIBODIES NEGATIVE PRIMARY BILIARY CIRRHOSISd. Journal of Hepatology, 2007, 46, S251-S252.	1.8	0
87	Hepatitis C and autoreactivity. Digestive and Liver Disease, 2007, 39, S22-S24.	0.4	21
88	Antibodies to SSâ€A/Roâ€52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Alimentary Pharmacology and Therapeutics, 2007, 26, 831-838.	1.9	77
89	Evidence of a Genetic Basis for the Different Geographic Occurrences of Liver/Kidney Microsomal Antibody Type 1 in Hepatitis C. Digestive Diseases and Sciences, 2007, 52, 179-184.	1.1	26
90	Diagnostic accuracy of anti-nuclear antibodies giving a multiple nuclear dots (MND) or a membranous (RL/M) pattern in primary biliary cirrhosis. Digestive and Liver Disease, 2006, 38, A75.	0.4	0

#	Article	IF	CITATIONS
91	Natural course and incidence of non-organ specific autoantibodies (NOSA) and HCV infection in the general population: A nested case-control study of the dionysos cohort. Digestive and Liver Disease, 2006, 38, A78-A79.	0.4	0
92	Anti-extractable nuclear antigens (ENA) antibodies in primary biliary cirrhosis. Digestive and Liver Disease, 2006, 38, A80-A81.	0.4	0
93	Antinuclear antibodies giving the 'multiple nuclear dots' or the 'rim-like/membranous' patterns: diagnostic accuracy for primary biliary cirrhosis. Alimentary Pharmacology and Therapeutics, 2006, 24, 1575-1583.	1.9	65
94	Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. Journal of Clinical Pathology, 2006, 59, 280-284.	1.0	83
95	Immunoglobulin GM and KM Allotypes and Prevalence of Anti-LKM1 Autoantibodies in Patients with Hepatitis C Virus Infection. Journal of Virology, 2006, 80, 5097-5099.	1.5	5
96	Steatosis in chronic hepatitis C. Gut, 2006, 55, 1047; author reply 1047-8.	6.1	0
97	Anti-saccharomyces cerevisiae antibodies (ASCA) in coeliac disease. Gut, 2006, 55, 296.	6.1	17
98	Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free diet. Alimentary Pharmacology and Therapeutics, 2005, 21, 881-887.	1.9	51
99	Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Alimentary Pharmacology and Therapeutics, 2005, 21, 1273-1277.	1.9	60
100	Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin. Alimentary Pharmacology and Therapeutics, 2005, 22, 943-949.	1.9	11
101	Acute Icteric Hepatitis Induced By a Short Course of Low-Dose Cyclophosphamide in a Patient with Lupus Nephritis. Digestive Diseases and Sciences, 2005, 50, 2364-2365.	1.1	12
102	Genetic distinctions between autoimmune hepatitis in Italy and North America. World Journal of Gastroenterology, 2005, 11, 1862.	1.4	70
103	Clinical Impact of NonOrgan-Specific Autoantibodies on the Response to Combined Antiviral Treatment in Patients with Hepatitis C. Clinical Infectious Diseases, 2005, 40, 501-507.	2.9	57
104	Susceptibility to Thyroid Disorders in Hepatitis C. Clinical Gastroenterology and Hepatology, 2005, 3, 595-603.	2.4	57
105	The Western immunoblotting pattern of anti-mitochondrial antibodies is independent of the clinical expression of primary biliary cirrhosis. Digestive and Liver Disease, 2005, 37, 108-112.	0.4	19
106	Response to Dr. Bogdanos. American Journal of Gastroenterology, 2004, 99, 765-765.	0.2	0
107	Serum Antibody Reactivity to Human Intracisternal A-Type Particle Retrovirus Proteins in Systemic Sclerosis Patients. Acta Dermato-Venereologica, 2004, 84, 177-180.	0.6	7
108	Anti-actin IgA antibodies in severe coeliac disease. Clinical and Experimental Immunology, 2004, 137, 386-392.	1.1	58

#	Article	IF	CITATIONS
109	Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver International, 2004, 24, 322-329.	1.9	80
110	'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?. Clinical and Experimental Immunology, 2004, 135, 154-158.	1.1	79
111	Specificity of antiâ€sp100 antibody for primary biliary cirrhosis. Scandinavian Journal of Gastroenterology, 2004, 39, 405-406.	0.6	20
112	Antitransglutaminase Antibodies and Giardiasis. American Journal of Gastroenterology, 2004, 99, 2505-2506.	0.2	21
113	Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the 'acute' type. QJM - Monthly Journal of the Association of Physicians, 2004, 97, 407-412.	0.2	79
114	Multiple Viral/Self Immunological Cross-Reactivity in Liver Kidney Microsomal Antibody Positive Hepatitis C Virus-Infected Patients is Associated with the Possession of HLA B51. International Journal of Immunopathology and Pharmacology, 2004, 17, 83-92.	1.0	81
115	Prevalence of non-organ specific autoantibodies in HCV-infected subjects in the general population. Clinical and Experimental Immunology, 2003, 131, 118-121.	1.1	41
116	Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clinical and Experimental Immunology, 2003, 132, 473-476.	1.1	84
117	Enhanced monocyte Th1 cytokine production in HCV-infected cryoglobulinemic patients. Journal of Hepatology, 2003, 38, 230-236.	1.8	27
118	Biochemical and histological hepatic disease activity in cryoglobulinemic patients. Journal of Hepatology, 2003, 38, 157.	1.8	0
119	Hepatitis C virus infection associated with liver-kidney microsomal antibody type 1 (LKM1) autoantibodies in children. Journal of Pediatrics, 2003, 142, 185-190.	0.9	54
120	Non–Organ-Specific Autoantibodies in Children with Chronic Hepatitis C: Clinical Significance and Impact on Interferon Treatment. Clinical Infectious Diseases, 2003, 37, 1320-1326.	2.9	53
121	Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. American Journal of Gastroenterology, 2003, 98, 431-437.	0.2	188
122	Cytochrome P4502D6193–212: A New Immunodominant Epitope and Target of Virus/Self Cross-Reactivity in Liver Kidney Microsomal Autoantibody Type 1-Positive Liver Disease. Journal of Immunology, 2003, 170, 1481-1489.	0.4	196
123	Celiac disease in autoimmune cholestatic liver disorders. American Journal of Gastroenterology, 2002, 97, 2609-2613.	0.2	136
124	Smooth Muscle Antibodies and Type 1 Autoimmune Hepatitis. Autoimmunity, 2002, 35, 497-500.	1.2	63
125	Key Residues of a Major Cytochrome P4502D6 Epitope Are Located on the Surface of the Molecule. Journal of Immunology, 2002, 169, 277-285.	0.4	74
126	The Hepatitic/Cholestatic "Overlap" Syndrome: An Italian Experience. Autoimmunity, 2002, 35, 565-568.	1.2	44

#	Article	IF	CITATIONS
127	Spontaneous remission of autoimmune hepatitis during pregnancy. Digestive and Liver Disease, 2002, 34, 608-609.	0.4	19
128	Clinical presentation of autoimmune hepatitis (AIH). Journal of Hepatology, 2002, 36, 262-263.	1.8	0
129	New autoantibodies and autoantigens in autoimmune hepatitis. Clinics in Liver Disease, 2002, 6, 785-797.	1.0	13
130	Autoantibody appearance in cytomegalovirus-infected liver transplant recipients: Correlation with antigenemia. Journal of Medical Virology, 2002, 66, 56-62.	2.5	41
131	Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibodies in hepatic and rheumatological disorders. Clinical and Experimental Immunology, 2002, 127, 172-175.	1.1	46
132	A new route to apoptosis in hepatitis C virus infection. Journal of Hepatology, 2001, 35, 814-815.	1.8	5
133	Antilactoferrin antibodies in autoimmune liver disease. Clinical and Experimental Immunology, 2001, 124, 470-473.	1.1	23
134	Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology, 2001, 34, 494-501.	3.6	59
135	Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut, 2000, 46, 553-561.	6.1	96
136	Does the presence of non-organ specific autoantibodies (NOSA) correlate with disease activity in HCV infected patients?. Journal of Hepatology, 2000, 32, 218.	1.8	0
137	Hepatitis C virus and autoimmunity. Hepatology, 2000, 31, 1380-1380.	3.6	10
138	Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut, 1999, 45, 435-441.	6.1	145
139	A novel assay for detecting antibodies to cytochrome P4502D6, the molecular target of liver kidney microsomal antibody type 1. Journal of Immunological Methods, 1999, 223, 227-235.	0.6	11
140	Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Digestive Diseases and Sciences, 1998, 43, 2190-2195.	1.1	158
141	Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut, 1998, 42, 721-726.	6.1	109
142	Haplotype HLA-B8-DR3 Confers Susceptibility to Hepatitis C Virus-Related Mixed Cryoglobulinemia. Blood, 1998, 91, 2062-2066.	0.6	82
143	Antibodies to carbonic anhydrase in autoimmune cholangiopathy. Gastroenterology, 1997, 112, 1053-1054.	0.6	22
144	Establishment of a novel radioligand assay using eukaryotically expressed cytchrome P4502D6 for the measurement of liver kidney microsomal type 1 antibdy in patients with autoimmune hepatitis and hepatitis C virus infection. Journal of Hepatology, 1997, 26, 1396-1402.	1.8	49

#	Article	IF	CITATIONS
145	Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology, 1997, 25, 1105-1107.	3.6	125
146	Serum autoantibodies in chronic hepatitis C: Comparison with autoimmune hepatitis and impact on the disease profile. Hepatology, 1997, 26, 561-566.	3.6	225
147	Serum autoantibodies in chronic hepatitis C: Comparison with autoimmune hepatitis and impact on the disease profile. Hepatology, 1997, 26, 561-566.	3.6	22
148	Low hepatitis C viremia levels in patients with anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis. Journal of Hepatology, 1996, 25, 433-438.	1.8	23
149	Non-organ specific autoantibodies in children with chronic hepatitis C. Journal of Hepatology, 1996, 25, 614-620.	1.8	85
150	Quantification of hepatitis C virus-infected peripheral blood mononuclear cells by in situ reverse transcriptase-polymerase chain reaction. Blood, 1996, 88, 2768-2774.	0.6	73
151	Impact of International Autoimmune Hepatitis Group scoring system in definition of autoimmune hepatitis. Digestive Diseases and Sciences, 1996, 41, 166-171.	1.1	35
152	Quantification of hepatitis C virus-infected peripheral blood mononuclear cells by in situ reverse transcriptase-polymerase chain reaction. Blood, 1996, 88, 2768-74.	0.6	17
153	Detection of anti-liver cytosol antibody type 1 (anti-LC1) by immunodiffusion, counterimmunoelectrophoresis and immunoblotting: comparison of different techniques. Journal of Immunological Methods, 1995, 187, 259-264.	0.6	51
154	Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection Gut, 1995, 36, 749-754.	6.1	77
155	Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease Gut, 1995, 37, 406-412.	6.1	75
156	Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. Journal of Hepatology, 1994, 21, 199-203.	1.8	99
157	Analysis of the hepatitis C virus genome in patients with anti-LKM-1 autoantibodies. Journal of Hepatology, 1994, 21, 273-276.	1.8	33
158	Testing for hepatitis C virus sequences in peripheral blood mononuclear cells of patients with chronic hepatitis C in the absence of serum hepatitis C virus RNA. Liver, 1994, 14, 124-128.	0.1	43
159	LKM1 appearance in a HLA-DR3+ patient with chronic hepatitis C during interferon treatment. Journal of Hepatology, 1993, 18, 259-260.	1.8	21
160	Serum autoantibodies and the diagnosis of type-1 autoimmune hepatitis in Italy: a reappraisal at the light of hepatitis C virus infection Gut, 1992, 33, 1260-1263.	6.1	41